Living on a GLP-1: Daily Life With Wegovy or Zepbound

Living on Wegovy or Zepbound is mostly a weekly rhythm rather than a daily one: one injection on the same day each week, a refrigerator at home, and a stack of insurance and refill paperwork that can interrupt treatment more than the drug itself does. The prescribing labels answer the practical questions about missed doses, changing your injection day, and how long each product can sit out of the fridge. Beyond the labels, surveys and observational studies describe what people report about work, appearance, mood, and other people’s reactions.

The evidence that exists is uneven. A 2026 systematic review of injection timing screened 1,000 records and concluded that the available evidence does not support a specific optimal day of the week ^[1]. Two published analyses of one employee survey, the PERCEPTIONS survey, describe real-world experiences of people starting tirzepatide ^[4][5], alongside a separate continuity survey of patients with prescription gaps ^[6] and a 48-week French cohort linking digital engagement to staying on treatment ^[7].

What day of the week should I take my shot?

A 2026 systematic review in Medicina identified 1,471 records, screened 1,000 unique papers, and included only three studies — the SUSTAIN 4 trial, a case series on alternate-day oral semaglutide, and an expert panel discussion. The review’s conclusion is that current evidence does not support a specific optimal day of the week for semaglutide or tirzepatide administration, and that flexible schedules matched to a person’s preferences may support adherence — a suggestion that rests on expert opinion and indirect evidence rather than head-to-head data ^[1].

The labels take slightly different positions. The Wegovy label directs patients to inject once weekly, on the same day each week, at any time of day, with or without meals ^[2]. The Zepbound label states that the day of weekly administration can be changed, if necessary, as long as at least 3 days (72 hours) pass between the two doses ^[3]. Any decision to change your injection day is one to make with your prescriber or pharmacist.

What do the labels say about a missed dose?

The two labels give different windows, and each applies only to its own product. For Wegovy injection, the label says that if one dose is missed and the next scheduled dose is more than 2 days (48 hours) away, the missed dose should be administered as soon as possible; if the next scheduled dose is less than 2 days away, the dose should be skipped and dosing resumed on the regular day. If 2 or more consecutive doses are missed, the label directs reinitiating dose escalation at a lower dosage to reduce the risk of gastrointestinal adverse reactions — a prescriber decision ^[2].

For Zepbound, the label says a missed dose should be administered as soon as possible within 4 days (96 hours); if more than 4 days have passed, the missed dose should be skipped and the next dose taken on the regularly scheduled day, after which the weekly schedule resumes ^[3]. If you miss a dose, the label text is what to bring to your prescriber or pharmacist, not a decision to make on your own.

Both labels list gastrointestinal reactions — nausea, diarrhea, vomiting, and constipation — among the most common adverse reactions, occurring in 5% or more of patients ^[2][3].

How long can my medication stay out of the fridge when I travel?

Each product has its own limits, and the days and temperatures do not transfer between them. Both labels say to store the medication in a refrigerator at 36°F to 46°F (2°C to 8°C), to keep it in the original carton to protect it from light, and never to freeze it or use it if it has been frozen ^[2][3].

Product	Refrigerated storage	Out of the fridge	Discard if
Wegovy single-dose pen or syringe [2]	36°F to 46°F (2°C to 8°C)	Up to 28 days at 46°F to 86°F (8°C to 30°C), before cap removal, in the original carton	Frozen, exposed to light or temperatures above 86°F, or out of the refrigerator 28 days or longer
Wegovy FlexTouch multi-dose pen [2]	36°F to 46°F before first use	After first use, 56 days at 59°F to 86°F (15°C to 30°C), or refrigerated	Frozen, exposed to light or above 86°F, or out of the refrigerator 56 days or longer
Zepbound single-dose pen or vial [3]	36°F to 46°F (2°C to 8°C)	Up to a total of 21 days at temperatures not above 86°F (30°C)	After a total of 21 days at room temperature
Zepbound multi-dose vial or KwikPen [3]	36°F to 46°F (2°C to 8°C)	Unopened: 30 days at up to 86°F. Opened: discard after 30 days at room temperature, 30 days after first use, or after 4 weekly doses, whichever comes first	Frozen

A few handling details from the Zepbound instructions for use: the pen has glass parts, so if it is dropped on a hard surface it should not be used, and it is not necessary to warm the pen to room temperature before injecting ^[3]. For travel coolers, hotel refrigerators, and crossing time zones, a pharmacist is the right person to ask.

How does working full time fit into treatment?

The clearest picture comes from the PERCEPTIONS survey, which enrolled 518 full-time employed US adults starting tirzepatide for obesity, surveyed between June and November 2025 within 4 to 8 weeks of their first dose (mean about 26 days). Their mean age was 46.0, mean BMI 38.4, 78.2% were female, and 69.5% were White ^[4][5].

On a work-productivity questionnaire, participants reported overall work impairment of 32.4% and activity impairment of 43.0%, driven mainly by presenteeism — reduced performance while at work. These numbers were measured at treatment start, so they reflect the burden of obesity before the drug had any effect, not a drug effect ^[4].

On insurance, among the 80.9% with employer-provided insurance, 55.9% reported that their plan covered obesity medication; 96.5% said employer plans should cover it; 81.7% said coverage might raise their job satisfaction; and 52.3% said they would consider changing jobs to get coverage ^[4]. The main motivators for starting treatment were overall health and well-being (83.8%), physical functioning (58.3%), and self-confidence or appearance outside work (51.4%); the main barriers were insurance coverage (90%) and treatment cost (57.7%). Most found the product easy to use — 98.0% of auto-injector users and 95.8% of vial users ^[5]. That paper’s copyright is held by Eli Lilly and Company, the manufacturer, so it is manufacturer-connected research ^[5].

Why did my pharmacy or insurer delay my refill?

A survey at an academic medical center asked adults with a GLP-1 receptor agonist prescription who had a prescription gap longer than 90 days about their experience. Of 4,890 people invited, 261 completed the survey — a 5.3% response rate — and 143 (54.8%) were current users of a weight-management medication ^[6].

Prior authorization was the biggest reported obstacle: 159 participants (60.9%) faced a prior-authorization requirement, and of those, 79 (49.7%) either waited more than 7 days or were never approved. Among current users, 32.4% reported a medication gap of 14 days or more ^[6]. Because the sample was deliberately recruited from people who had a gap, these figures describe that group’s experience, not a population rate.

Participants described the disruptions as process failures: prior-authorization delay, out-of-pocket cost, pharmacy stock-outs, dispensing delays, and fragmented coordination across clinics. The weakest-rated items were cross-clinic coordination (54.1%) and visibility into required next steps (52.2%). The most-wanted digital features were all-in-one tracking of refills, prior authorization, and appointments (89.5%) and real-time prior-authorization status (87.2%) ^[6].

Does tracking with an app change results?

One observational study connects engagement to staying on treatment, but it does not show that an app causes weight loss. A 48-week single-center cohort in Montpellier followed 191 adults with a BMI of 40 or over (mean 45.7), mean age 51.7, 31.9% male, all starting semaglutide 2.4 mg through the French early-access program. Engagement was measured with the Aviitam structured assessment platform — a clinical questionnaire platform, not a consumer tracking app ^[7].

At 48 weeks, 74.3% were still on semaglutide, and 87.3% of those who persisted reached the 2.4 mg dose. Persistence rose with engagement level: 59.5% among those who never used the platform, 71.9% among partial users, and 79.5% among full users (P=.02), with an adjusted odds ratio of 1.62 per engagement step. Mean weight loss was 11.8% in the whole cohort and 14.6% among persistent participants, ranging from 3.9% in discontinuers to 15.3% at the full 2.4 mg dose ^[7].

The mediation analysis is the key caveat: persistence explained about 69% of the association between engagement and weight loss, and the direct effect of engagement was not significant. In other words, people who engaged more lost more weight mainly because they stayed on the drug longer — and because the design is observational, engagement may simply mark motivation. The paper’s background notes that real-world 12-month persistence with GLP-1 receptor agonists runs 32% to 50%, and fewer than 15% of patients reach the 2.4 mg target dose ^[7].

What do tracking apps actually do?

A 2026 review in Current Obesity Reports found that apps and wearables reduce the burden of self-monitoring and that telehealth removes access barriers, but that low engagement is a persistent problem with digital interventions — making engagement itself the priority for future research ^[8]. Diet-tracking apps passed 3.6 billion downloads in 2024, and the weight-loss app market is worth about $4.6 billion, expected to double by 2034; many apps charge for advanced features ^[8].

One documented example is MyFitnessPal’s GLP-1 Support feature, which logs dose, time, and injection site alongside food, with optional reminders and side-effect tracking by severity. The dose unit is milligrams only, and the feature is available in the United States (iOS and Android) and Canada (iOS), in English only ^[16]. MyFitnessPal states that it does not verify medication, dose, or timing, and does not alert users to missed doses, interactions, or side effects — the entries are user-entered reference only ^[16]. WeightWatchers also offers a GLP-1 Companion Program ^[17].

What changes show up beyond the scale?

A BMJ network meta-analysis published in July 2026 pooled 262 randomized trials with 99,791 participants across 19 drugs, with searches through 12 November 2025 and follow-up from 12 to 172 weeks. At one year versus lifestyle modification alone, tirzepatide produced a mean weight difference of -14.9% and subcutaneous semaglutide -9.8% ^[10].

On quality of life, the picture is more reserved. Across 43 trials with 45,663 participants, no drug convincingly improved quality of life beyond the minimally important difference — all mean differences were under 5 points on a scale where the minimally important difference is 10 ^[10]. Tirzepatide reduced fat mass the most (by 25.7%) but also lean mass the most (by 8.3%), and fatigue risk increased with several drugs. Subcutaneous semaglutide was the only drug associated with reduced all-cause mortality (risk ratio 0.81) and myocardial infarction (risk ratio 0.72), estimates drawn largely from cardiovascular outcome trials in high-risk populations ^[10].

What happens to skin, face, hair, and muscle?

An anonymous survey run from April to May 2025 collected responses from 1,226 patients on weight-management medication through a national telemedicine platform — 80.3% female, 85.1% White, 60.0% on a GLP-1 receptor agonist only. Of these, 61.9% reported at least one concern: skin sagging 37.7% (most often the arms), facial volume loss 29.2%, hair loss 28.9%, worse skin quality 24.1%, and less muscle strength 17.9% ^[11].

Concerns rose with the amount of weight lost: 90.9% of those who lost more than 20% of total body weight reported at least one concern, versus 50.5% of those who lost under 10%. In the 10-to-20% weight-loss group, 76.6% of GLP-1 receptor agonist users reported a concern versus 52.1% of non-users. The authors flag real limits: the survey was voluntary, with selection and recall bias, and the rate of weight loss was not recorded ^[11].

A review in Aesthetic Plastic Surgery covering 40 studies through May 2025 described facial volume loss, dermal thinning, loss of collagen and elastin, and reduced skin elasticity, with risk factors including advanced age, a long history of obesity, rapid weight loss, poor hydration, and low protein intake. It proposes gradual weight loss, nutrition, hydration, and early dermatologic evaluation; a correction to the paper was published on 20 July 2026 ^[12]. Hair loss is listed among the common adverse reactions (5% or more) on both the Wegovy and Zepbound labels ^[2][3].

What happens when I tell people I take Ozempic?

One experiment tested this directly. In a 2026 study in Social Science & Medicine, 297 participants — 78.8% women, mean age 20.2, 42.4% with a BMI over 25 — were randomly assigned to read one of three vignettes about a woman who lost weight and later regained it through bariatric surgery, Ozempic, or diet and exercise. The Ozempic version was rated more negatively, and the woman was assumed to be less healthy, than in the diet-and-exercise version. There was no difference for the bariatric surgery version compared with the others. Participants also underestimated how common weight regain is. The authors declared no funding or conflicts, and the sample of mostly college-age women limits how far the findings generalize ^[13].

A 2026 commentary in the International Journal of Obesity describes “shortcut” and “easy way out” narratives around GLP-1 medications, arguing that GLP-1-related stigma is a distinct form of weight stigma in which judgments extend to the perceived legitimacy and moral worthiness of using medication. The authors write that this compounded stigma may add to harm and deter treatment, and they call for research to define and measure it ^[14].

Can these drugs affect mood and motivation?

A 2026 case series in Obesity Pillars describes three women on tirzepatide 15 mg weekly who reported reduced motivation, emotional flatness, and loss of interest in exercise and enjoyable activities despite losing weight. Two had no history of mood disorders; one had a history of depression and anxiety. The symptoms appeared after prolonged treatment at or near the maximum dose. Their prescribers reduced the dose to 10 mg or lower; two improved on dose reduction alone, and one also needed bupropion. Re-escalating the dose in one patient brought the symptoms back, and weight was maintained throughout. The authors suggest that such symptoms may occur in a subset of patients on high-dose tirzepatide and that clinicians should consider monitoring motivation and reward perception at higher doses ^[15]. It is worth noting that the report covers three patients, so the evidence base here is small.

If you notice changes like these, the case series is a reason to raise them with your prescriber rather than to adjust anything yourself. On both the Wegovy and Zepbound labels, the Suicidal Behavior and Ideation warning was removed in February 2026 ^[2][3].

When should a day-to-day question go to my prescriber or pharmacist?

Both labels state that concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia, and that reducing the dose of those other drugs may be necessary ^[2][3]. The day-of-week review reported no quantitative adherence or adverse-event data tied to any particular injection day among its included studies ^[1].

For practical questions — travel coolers, hotel mini-fridges, crossing time zones, shift work, or how side effects fit a particular workload — a pharmacist or prescriber is the person to ask, along with any question about a missed dose, a dose change, or a change of injection day.

Sources

1. Medicina. Is there a better day of the week to administer semaglutide or tirzepatide? A systematic literature review.
2. National Library of Medicine DailyMed. WEGOVY (semaglutide) injection, solution and tablet. Drug label.
3. National Library of Medicine DailyMed. ZEPBOUND (tirzepatide) injection, solution and ZEPBOUND KWIKPEN. Drug label.
4. Obesity Pillars. Employee perceptions and experiences with tirzepatide treatment for obesity or overweight in the US: Insights from the PERCEPTIONS Survey. September 2026.
5. Obesity Pillars. Understanding reasons for initiation and experience with tirzepatide among individuals with obesity or overweight: Results from the PERCEPTIONS survey. September 2026.
6. Obesity Science & Practice. Patient-reported continuity of GLP-1 receptor agonist therapy. 2026.
7. Journal of Medical Internet Research. Digital engagement and predictors of semaglutide persistence and weight loss in severe obesity: 48-week observational study. August 26, 2026.
8. Current Obesity Reports. Digital health in obesity care: Current evidence, challenges, and future directions. September 10, 2026.
9. SLEEP. Changes in patient-reported outcomes and objective assessments based on baseline symptom severity in SURMOUNT-OSA: Post-hoc analyses.
10. The BMJ. Comparative effects of drugs for adults with overweight or obesity: Systematic review and network meta-analysis. July 8, 2026.
11. International Journal of Women’s Dermatology. Aesthetic, muscle, and dermatologic effects of medical weight management: Patient-reported outcomes shape a holistic preventive procedural approach. October 2026.
12. Aesthetic Plastic Surgery. Effects of GLP-1 receptor agonists on skin quality: A comprehensive literature review. May 20, 2026.
13. Social Science & Medicine. Compounding stigma: An experimental study comparing perceptions of an individual using Ozempic, bariatric surgery, or behavior modification. October 2026.
14. International Journal of Obesity. GLP-1 receptor agonists and the emergence of treatment-related stigma: A call for conceptual clarity.
15. Obesity Pillars. Resolution of anhedonia-like symptoms in patients treated for obesity with tirzepatide: A three-case series. September 2026.
16. MyFitnessPal Help. GLP-1 Support.
17. WeightWatchers. Welcome to the GLP-1 Companion Program.